Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Rhea-AI Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) will report full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 a.m. ET before U.S. markets open. Management will host a conference call to review results and provide a business update.
Call hosts: David P. Luci, President and CEO, and Robert G. Shawah, CFO. Toll-free U.S. access and international participant numbers are provided for investors.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ACXP gained 3.68% while peers showed mixed moves: NCNA up 4.33% and ARTL down 5.59%. With only one peer up and one down in the momentum scan and no same-day peer news, the price action appears more company-specific than sector-driven.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 27 | Earnings call notice | Neutral | +1.4% | Scheduled Q3 2025 results call and business update before market open. |
| Jul 24 | Earnings call notice | Neutral | -1.1% | Announced Q2 2025 results call with leadership-hosted business update. |
| Apr 30 | Earnings call notice | Neutral | +2.4% | Set date and details for Q1 2025 results conference call. |
| Feb 28 | Earnings call notice | Neutral | +3.4% | Scheduled Q4 and full year 2024 results call and business update. |
| Jul 16 | Earnings call notice | Neutral | +3.4% | Announced Q2 2024 results call and business update before market open. |
For prior conferences,earnings call announcements, ACXP has typically shown modest single-day moves, with an average reaction of about 1.88%, suggesting these scheduling releases have had limited but generally positive impact.
Recent ACXP history for conferences,earnings shows a consistent pattern of announcing quarterly and annual results calls at 8:00 a.m. ET before the U.S. market open, led by the same CEO and CFO team. Past call-scheduling releases on May 13, 2025, August 12, 2025, and March 18, 2025 produced modest single-day moves, mostly positive. Today’s full year and Q4 2025 call notice fits this established cadence and communication style.
Historical Comparison
In the past, ACXP’s earnings-call scheduling headlines under the same tag saw average moves of 1.88%. Today’s 3.68% gain is above that typical reaction but still within a modest, non-extreme range.
The company has maintained a regular cadence of quarterly and annual conference calls led by the same executives, reinforcing a stable communication pattern around financial reporting.
Regulatory & Risk Context
ACXP has an effective Form S-3 shelf filed on July 9, 2025 allowing issuance of up to $50 million in various securities over three years. Capacity is constrained by a public float of $21.9 million, limiting sales in any 12-month period to roughly one-third of float under Form S-3 rules, and the company has already raised $5.48 million within the current 12‑month window. This framework enables additional capital raises that could be dilutive.
Market Pulse Summary
This announcement sets the date and access details for discussing full year and Q4 2025 results, continuing ACXP’s pattern of quarterly conferences,earnings calls at 8:00 a.m. ET. Historically, such notices produced modest moves averaging 1.88%. In the background, investors must weigh capital needs and dilution risk from the $50 million shelf and $12.0 million Lincoln Park agreement, as well as prior going‑concern language in SEC filings.
AI-generated analysis. Not financial advice.
David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
Date: Friday, March 13, 2026
Time: 8:00 a.m. ET
Toll free (
Click here for participant International Toll-Free access numbers
About Ibezapolstat
Ibezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. As previously announced, the Company has received final EMA and FDA advice for our ibezapolstat pivotal Phase 3 trials. Their advice included and confirmed the non-inferiority study design elements, the patient population, primary and secondary endpoints, and size of the registration safety database. Acurx also now has a clear international roadmap for conduct of its Phase 3 program and, if successful, requirements for US NDA submission and EU Marketing Authorization.
Acurx previously announced that it had received positive regulatory guidance from EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program
In June 2018, ibezapolstat was designated by the
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:SOURCE Acurx Pharmaceuticals, Inc.
FAQ
When will Acurx (ACXP) release full year and Q4 2025 results and hold the conference call?
Who will host the Acurx (ACXP) March 13, 2026 conference call and what will they discuss?
How can investors join the Acurx (ACXP) March 13, 2026 conference call?
What time zone is the Acurx (ACXP) March 13, 2026 earnings call scheduled in?
Will Acurx (ACXP) discuss forward guidance during the March 13, 2026 call?
What is the Acurx (ACXP) conference call Access ID for March 13, 2026?
